Search

The article discusses a randomized controlled trial aimed at comparing the safety and immunogenicity of four intramuscular double-dose regimen and four intradermal low-dose regimen against the standard hepatitis B vaccine regimen in adults with human immunodeficiency virus 1 (HIV-1) infection. The trial was conducted in France from June 28, 2007 to October 23, 2008. The percentage of responders at the 28th week was defined as patients with hepatitis B surface antibody (anti-HBs) of at least 10 milli-international unit/milliliter (mIU/ml) in patients given at least one dose of vaccine. The trial found an improved serological response among patients in the four intramuscular double-dose and the four intradermal low-dose regimens compared with the standard HBV vaccine regimen.